Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease cystic fibrosis
Phenotype C0024115|lung disease
Sentences 65
PubMedID- 20811560 Tuberculosis, including tuberculosis bronchiectasis, bronchogenic carcinoma, and chronic inflammatory lung disease due to bronchiectasis, cystic fibrosis, or aspergillosis are the most common causes of massive hemoptysis [19].
PubMedID- 25973994 Nocardia is often associated with significant lung disease in cystic fibrosis, possibly associated with allergic bronchopulmonary aspergillosis or steroids.
PubMedID- 25216826 Mycobacterium abscessus complex is a group of rapidly growing mycobacteria, and an emerging cause of non-tuberculous mycobacterial lung disease in patients with cystic fibrosis and chronic lung diseases, such as bronchiectasis.
PubMedID- 20427819 The development of lung disease in cystic fibrosis pigs.
PubMedID- 20693248 Outcome measures to assess therapeutic interventions in cystic fibrosis (cf) patients with mild lung disease are lacking.
PubMedID- 26047144 Background: lung disease in cystic fibrosis (cf) involves excessive inflammation, repetitive infections and development of bronchiectasis.
PubMedID- 24429095 We discuss treatment strategies including new drugs that are being developed and their potential role in the treatment of early lung disease in patients with cystic fibrosis.
PubMedID- 20717938 Summary: lung disease in patients with cystic fibrosis (cf) is characterized by recurrent bacterial respiratory infections and intense airway inflammation.
PubMedID- 22241570 Background: gastro-esophageal reflux (gor) may contribute to lung disease in children with cystic fibrosis (cf).
PubMedID- 19931415 Fat-free mass depletion in cystic fibrosis: associated with lung disease severity but poorly detected by body mass index.
PubMedID- 20955240 It is the main cause of hospital-acquired pneumonia and of lung disease in patients with cystic fibrosis, as well as infections in patients with neutropenia and burns (pier and ramphal, 2005).
PubMedID- 25470304 Authors' conclusions: this review did not find any evidence for the effectiveness of different antimicrobial treatment for nontuberculous mycobacteria lung disease in people with cystic fibrosis.
PubMedID- 25861303 cystic fibrosis is associated with chronic lung disease, poor digestion, malabsorption of nutrients, and malnutrition [3].
PubMedID- 26079395 Does the fef25-75 or the fef75 have any value in assessing lung disease in children with cystic fibrosis or asthma.
PubMedID- 26453627 Further issues that require attention are organ transplantation and end of life management.lung disease in adults with cystic fibrosis drives most of the clinical care requirements, and major life-threatening complications, such as respiratory infection, respiratory failure, pneumothorax and haemoptysis, and the management of lung transplantation require expertise from trained respiratory physicians.
PubMedID- 21494150 Purpose of review: lung disease in cystic fibrosis (cf) results from chronic airway infection and inflammation leading to progressive bronchiectasis and respiratory failure.
PubMedID- 23313410 The use of ivacaftor in an adult with severe lung disease due to cystic fibrosis (deltaf508/g551d).
PubMedID- 23226468 The university of north carolina committee for the rights of human subjects approved the collection and use of excess surgical pathology tissue, obtained at the time of lung transplant, from patients with advanced lung disease associated with cystic fibrosis.
PubMedID- 21955231 lung disease in cystic fibrosis (cf) is typified by the development of chronic airways infection culminating in bronchiectasis and progression to end-stage respiratory disease.
PubMedID- 23378408 Hrct has an advantage over conventional chest x-rays in the evaluation of the stage and progression of lung disease in patients with cystic fibrosis.
PubMedID- 20840889 Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: poor adherence and the need to address it.
PubMedID- 25339567 [mycobacterial lung disease in patients with cystic fibrosis--report of three cases].
PubMedID- 20435528 Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: three areas for future research which areas to target.
PubMedID- 24261460 Rationale: previous studies of risk factors for progression of lung disease in cystic fibrosis (cf) have suffered from limitations that preclude a comprehensive understanding of the determinants of cf lung disease throughout childhood.
PubMedID- 22645424 The pathogenesis of lung disease in cystic fibrosis is characterised by decreased airway surface liquid volume and subsequent failure of normal mucociliary clearance.
PubMedID- 21154377 Antioxidant micronutrients for lung disease in cystic fibrosis.
PubMedID- 25984165 Recent data indicate that azithromycin is beneficial in lung disease of cystic fibrosis because it directly suppresses excessive inflammation [3].
PubMedID- 19895389 Lung transplantation is the only life-prolonging therapy available for cystic fibrosis (cf) patients with end-stage lung disease.
PubMedID- 25102015 Antioxidant supplementation for lung disease in cystic fibrosis.
PubMedID- 21462361 Genetic studies of lung disease in cystic fibrosis (cf) are hampered by the lack of a severity measure that accounts for chronic disease progression and mortality attrition.
PubMedID- 21942462 Objective: guidelines recommend chronic use of tobramycin solution for inhalation (tsi) for cystic fibrosis (cf) patients with moderate-to-severe lung disease and persistent airway pseudomonas aeruginosa.
PubMedID- 23235684 Authors' conclusions: this review did not find any evidence for the effectiveness of different antimicrobial treatment for nontuberculous mycobacteria lung disease in people with cystic fibrosis.
PubMedID- 22323305 Rationale: unrecognized airway infection and inflammation in young children with cystic fibrosis (cf) may lead to irreversible lung disease; therefore early detection and treatment is highly desirable.
PubMedID- 23633344 Background: nebuliser systems are used to deliver medications to control the symptoms and the progression of lung disease in people with cystic fibrosis.
PubMedID- 23460012 As a result of their underlying lung disease, patients with cystic fibrosis (cf) have a higher risk of developing nontuberculous mycobacteria (ntm) infections compared with the general population.
PubMedID- 25222938 Pulmonary hypertension in cystic fibrosis with advanced lung disease.
PubMedID- 22960983 What you don't know can hurt you; early asymptomatic lung disease in cystic fibrosis.
PubMedID- 26383963 Association of chronic candida albicans respiratory infection with a more severe lung disease in patients with cystic fibrosis.
PubMedID- 24282073 Authors' conclusions: there is currently no evidence to support the use of cftr gene transfer agents as a treatment for lung disease in people with cystic fibrosis.
PubMedID- 25505695 These same challenges are likely to apply to treating infants, or adults with obstructed airways, with aerosolized gene vectors for other lung diseases.figure 3percent of people with cystic fibrosis by age with normal/mild forced expiratory volume in one second (fev1), moderate fev1and severe fev1.
PubMedID- 24062613 Background: high-producer tgfbeta1 genotypes are associated with severe lung disease in cystic fibrosis (cf), but studies combining il-8, tnfalpha-, and tgfbeta1(+genotype) levels and their impact on cf lung disease are scarce.
PubMedID- 21220215 Reports from the seventies and eighties have shown that cystic fibrosis (cf) patients with severe lung disease have high levels of igg and that this is associated with worse prognosis.
PubMedID- 24884656 Determinants of exercise capacity in cystic fibrosis patients with mild-to-moderate lung disease.
PubMedID- 25629612 Changes in the airway microbiome may be important in the pathophysiology of chronic lung disease in patients with cystic fibrosis.
PubMedID- 25478180 Background: lung clearance index (lci) derived from sulfur hexafluoride (sf6) multiple breath washout (mbw) is a sensitive measure of lung disease in people with cystic fibrosis (cf).
PubMedID- 26429870 The purpose of this study was to evaluate cardiorespiratory fitness and reasons for exercise curtailment in a contemporary adult cystic fibrosis (cf) cohort with mild lung disease.
PubMedID- 25124441 lung disease in people with cystic fibrosis (cf) is initiated by defective host defense that predisposes airways to bacterial infection.
PubMedID- 23743112 Pseudomonas aeruginosa in patients without cystic fibrosis is strongly associated with chronic obstructive lung disease.
PubMedID- 20634941 Most of the morbidity and mortality of cystic fibrosis patients results from the lung disease [3].
PubMedID- 23748649 Correlation between computed tomography expression of pulmonary hypertension and severity of lung disease in cystic fibrosis patients.

Page: 1 2